Author
Listed:
- Christopher G. Langendorf
(Protein Chemistry & Metabolism, St Vincent’s Institute of Medical Research, University of Melbourne)
- Kevin R. W. Ngoei
(Protein Chemistry & Metabolism, St Vincent’s Institute of Medical Research, University of Melbourne)
- John W. Scott
(Protein Chemistry & Metabolism, St Vincent’s Institute of Medical Research, University of Melbourne)
- Naomi X. Y. Ling
(Metabolic Signaling Laboratory, St Vincent’s Institute of Medical Research, University of Melbourne)
- Sam M. A. Issa
(Protein Chemistry & Metabolism, St Vincent’s Institute of Medical Research, University of Melbourne
Metabolic Signaling Laboratory, St Vincent’s Institute of Medical Research, University of Melbourne)
- Michael A. Gorman
(ACRF Rational Drug Discovery Centre, St Vincent’s Institute of Medical Research, University of Melbourne)
- Michael W. Parker
(ACRF Rational Drug Discovery Centre, St Vincent’s Institute of Medical Research, University of Melbourne)
- Kei Sakamoto
(Nestlé Institute of Health Sciences SA)
- Jonathan S. Oakhill
(Metabolic Signaling Laboratory, St Vincent’s Institute of Medical Research, University of Melbourne)
- Bruce E. Kemp
(Protein Chemistry & Metabolism, St Vincent’s Institute of Medical Research, University of Melbourne
Mary MacKillop Institute for Health Research Australian Catholic University, Victoria Parade)
Abstract
The metabolic stress-sensing enzyme AMP-activated protein kinase (AMPK) is responsible for regulating metabolism in response to energy supply and demand. Drugs that activate AMPK may be useful in the treatment of metabolic diseases including type 2 diabetes. We have determined the crystal structure of AMPK in complex with its activator 5-(5-hydroxyl-isoxazol-3-yl)-furan-2-phosphonic acid (C2), revealing two C2-binding sites in the γ-subunit distinct from nucleotide sites. C2 acts synergistically with the drug A769662 to activate AMPK α1-containing complexes independent of upstream kinases. Our results show that dual drug therapies could be effective AMPK-targeting strategies to treat metabolic diseases.
Suggested Citation
Christopher G. Langendorf & Kevin R. W. Ngoei & John W. Scott & Naomi X. Y. Ling & Sam M. A. Issa & Michael A. Gorman & Michael W. Parker & Kei Sakamoto & Jonathan S. Oakhill & Bruce E. Kemp, 2016.
"Structural basis of allosteric and synergistic activation of AMPK by furan-2-phosphonic derivative C2 binding,"
Nature Communications, Nature, vol. 7(1), pages 1-8, April.
Handle:
RePEc:nat:natcom:v:7:y:2016:i:1:d:10.1038_ncomms10912
DOI: 10.1038/ncomms10912
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:7:y:2016:i:1:d:10.1038_ncomms10912. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.